Cellectis S.A. (NASDAQ:CLLS) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Cellectis S.A. (NASDAQ:CLLS) have earned an average recommendation of “Moderate Buy” from the six research firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $7.00.

A number of research analysts have weighed in on CLLS shares. Citizens Jmp reissued a “market outperform” rating and issued a $8.00 target price on shares of Cellectis in a research note on Tuesday, April 14th. Barclays started coverage on shares of Cellectis in a research note on Thursday. They issued an “overweight” rating and a $9.00 target price on the stock. Jefferies Financial Group started coverage on shares of Cellectis in a research note on Tuesday, February 17th. They issued a “buy” rating and a $7.00 target price on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Cellectis in a research note on Monday, April 20th.

Cellectis Trading Down 1.1%

CLLS opened at $3.63 on Thursday. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.52 and a quick ratio of 1.52. The company’s 50 day simple moving average is $3.70 and its two-hundred day simple moving average is $4.03. Cellectis has a 1-year low of $1.33 and a 1-year high of $5.48. The firm has a market capitalization of $364.23 million, a price-to-earnings ratio of -5.42 and a beta of 2.94.

Cellectis (NASDAQ:CLLS) last released its earnings results on Monday, May 11th. The biotechnology company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.08. Cellectis had a negative net margin of 89.51% and a negative return on equity of 80.66%. The business had revenue of $7.55 million for the quarter, compared to analyst estimates of $11.04 million.

Institutional Trading of Cellectis

Institutional investors have recently made changes to their positions in the company. Marshall Wace LLP raised its position in shares of Cellectis by 1,610.3% during the 4th quarter. Marshall Wace LLP now owns 178,473 shares of the biotechnology company’s stock valued at $864,000 after buying an additional 168,038 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of Cellectis during the 4th quarter valued at approximately $15,385,000. Millennium Management LLC raised its position in shares of Cellectis by 61.9% during the 3rd quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock valued at $165,000 after buying an additional 22,080 shares during the period. Citadel Advisors LLC purchased a new stake in shares of Cellectis during the 3rd quarter valued at approximately $633,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Cellectis by 228.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company’s stock valued at $5,856,000 after buying an additional 3,284,409 shares during the period. Hedge funds and other institutional investors own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.